Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 4/20 | 0.53 |
| ▸ | MAOB | P27338 | 2/20 | 0.53 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.49 |
| ▸ | HDAC3 | O15379 | 5/20 | 0.49 |
| ▸ | HDAC4 | P56524 | 5/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 5/20 | 0.49 |
| ▸ | HDAC7 | Q8WUI4 | 5/20 | 0.49 |
| ▸ | HDAC2 | Q92769 | 5/20 | 0.49 |
| ▸ | HDAC10 | Q969S8 | 5/20 | 0.49 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.49 |
| ▸ | HDAC8 | Q9BY41 | 5/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 5/20 | 0.49 |
| ▸ | HDAC9 | Q9UKV0 | 5/20 | 0.49 |
| ▸ | HDAC5 | Q9UQL6 | 5/20 | 0.49 |
| ▸ | P2RY12 | Q9H244 | 2/20 | 0.49 |
| ▸ | DKK1 | O94907 | 1/20 | 0.49 |
| ▸ | CKS1B | P61024 | 1/20 | 0.47 |
| ▸ | SKP1 | P63208 | 1/20 | 0.47 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.47 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10144845 | 0.86 | BCHE (0.59) | BCHEMAOBHDAC3HDAC4HDAC1 | |
| SCHEMBL10175547 | 0.85 | HDAC6 (0.62) | BCHEMAOBHDAC3HDAC4HDAC1 | |
| SCHEMBL13538789 | 0.83 | P2RY12 (0.46) | DGAT2HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL10194575 | 0.83 | F10 (0.52) | BCHEMAOBHDAC3HDAC4HDAC1 | |
| SCHEMBL13535033 | 0.79 | MEN1 (0.55) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL10194552 | 0.79 | ACACB (0.45) | DGAT2HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL9883521 | 0.78 | HDAC1 (0.45) | DGAT2HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL10175644 | 0.78 | BCHE (0.47) | BCHEMAOBDGAT2HDAC3HDAC4 | |
| SCHEMBL9883532 | 0.78 | HDAC1 (0.50) | DGAT2HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL9883517 | 0.78 | HDAC1 (0.44) | DGAT2HDAC3HDAC4HDAC1HDAC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8394831-B2 | Carbonylamino-derivatives as novel inhibitors of histone deacetylase | JANSSEN PHARMACEUTICA, N.V. (BE) | 2013-03-12 | — | — | US | disclosed |
| US-8394831-B2 | Carbonylamino-derivatives as novel inhibitors of histone deacetylase | JANSSEN PHARMACEUTICA, N.V. (BE) | 2013-03-12 | — | — | US | disclosed |
| US-20120041001-A1 | CARBONYLAMINO-DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE | JANSSEN PHARMACEUTICA, NV (BE) | 2012-02-16 | — | — | US | disclosed |
| US-20120041001-A1 | CARBONYLAMINO-DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE | JANSSEN PHARMACEUTICA, NV (BE) | 2012-02-16 | — | — | US | disclosed |
| US-8071615-B2 | Carbonylamino-derivatives as novel inhibitors of histone deacetylase | JANSSEN PHARMACEUTICA N.V. (BE) | 2011-12-06 | — | — | US | disclosed |
| US-8071615-B2 | Carbonylamino-derivatives as novel inhibitors of histone deacetylase | JANSSEN PHARMACEUTICA N.V. (BE) | 2011-12-06 | — | — | US | disclosed |
| US-20090042920-A1 | CARBONYLAMINO-DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE | VAN EMELEN KRISTOF | 2009-02-12 | — | — | US | disclosed |
| US-20090042920-A1 | CARBONYLAMINO-DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE | VAN EMELEN KRISTOF | 2009-02-12 | — | — | US | disclosed |
| US-7446109-B2 | Carbonylamino-derivatives as novel inhibitors of histone deacetylase | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-11-04 | — | — | US | disclosed |
| US-7446109-B2 | Carbonylamino-derivatives as novel inhibitors of histone deacetylase | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042920-A1 | CARBONYLAMINO-DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE | HDAC1, HDAC3, HDAC11 | BCHE 1878/4885MAOB 413/4885DGAT2 4266/4885 |
| US-20120041001-A1 | CARBONYLAMINO-DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE | HDAC1, HDAC3, HDAC11 | BCHE 1878/4885MAOB 413/4885DGAT2 4266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.